Product monographs are being updated to include the risk of serious hypertension, myocardial infarction (MI), stroke and seizures in postpartum women taking cabergoline.
A Health Canada safety review assesses the potential risk of weight loss in children under age six who are prescribed off-label central nervous system stimulants for ADHD.
The clinical trial, published in JAMA Psychiatry Wednesday, found the treatment reduced depressive symptoms for more than 35% of participants, who received two 40-minute ketamine infusions over two weeks.
